Erratum

Kanjanapan Y, Yip D. Considerations for cancer immunotherapy during the COVID‐19 pandemic. Med J Aust 2020; 213: 390‐392. https://doi.org/10.5694/mja2.50805

In this Perspective, on page 391, the sentence “Current guidelines recommend ICI monotherapy to be delivered at increased dosing intervals, such as nivolumab four times per week and pembrolizumab six times per week” is incorrect. It should read: “Current guidelines recommend ICI monotherapy to be delivered at increased dosing intervals, such as nivolumab every four weeks and pembrolizumab every six weeks”.